Roche Considers Selling Cancer Data Specialist Flatiron Health Business, Highlights Challenges With Start-Up Acquisitions
Roche Considers Selling Cancer Data Specialist Flatiron Health Business, Highlights Challenges With Start-Up Acquisitions
Roche Holding AG (OTC:RHHBY) is reportedly contemplating the divestiture of Flatiron Health, a cancer data specialist Roche acquired in 2018 for $1.9 billion.
羅氏(ADR)正在考慮出售2018年以19億美元收購的癌症數據專家Flatiron Health。
The move underscores the complexities and potential pitfalls that large pharmaceutical companies encounter when investing in early-stage health technology firms.
此舉突顯了大型製藥公司在投資初期健康科技公司時遇到的複雜性和潛在風險。
Also Read: Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients.
此外閱讀：羅氏的新免疫療法未能顯示肺癌患者比默克的暢銷藥Keytruda獲益。
Flatiron Health was founded by two former executives from Alphabet Inc's (NASDAQ:GOOG) (NASDAQ:GOOGL) Google.
Flatiron Health由Alphabet Inc（納斯達克：GOOG）（納斯達克：GOOGL）谷歌的兩名前高管創立。
The company manages electronic patient records for numerous U.S. cancer clinics, boasting one of the most extensive repositories of cancer data.
該公司管理着許多美國癌症診所的電子病歷，擁有最廣泛的癌症數據庫之一。
The start-up mines this data and sells it to pharmaceutical companies to aid in research and development.
這家初創企業開採這些數據並將其出售給製藥公司以協助研究和開發。
Roche's acquisition of Flatiron has not been without its challenges. Despite operating as a separate legal entity, Flatiron's association with Roche has deterred some rival drugmakers from engaging with the start-up, impacting its sales.
羅氏收購Flatiron並非沒有遇到挑戰。儘管作爲獨立的法人實體運營，但Flatiron與羅氏的聯繫已經阻礙了一些競爭對手與該初創企業進行交流，影響其銷售。
Flatiron generates approximately two-thirds of its revenue from selling data to pharmaceutical companies, a business model similar to that of Warburg Pincus-backed Modernizing Medicine, which has seen profitable returns for private equity investors.
Flatiron大約有三分之二的營業收入來自向製藥公司出售數據的業務模式，這與華爾街重金投資人支持的現代醫學類似，他們已經在股權投資方面看到了盈利的回報。
The departure of key Roche executives who initially supported the Flatiron acquisition has left the company with fewer advocates within Roche.
最初支持Flatiron收購的關鍵羅氏高管的離職已經讓該公司的支持者減少。
The Financial Times report adds that Roche is collaborating with Citigroup Inc (NYSE:C) to explore strategic options for Flatiron, including a potential divestiture or partial sale to a partner who can assist in managing the business.
《金融時報》的報道補充稱，羅氏正在與花旗集團（紐交所：C）合作，探討Flatiron的戰略選擇，包括潛在的剝離或部分出售給能夠協助管理業務的合作伙伴。
Despite its financial struggles, Flatiron's data has significantly contributed to Roche's cancer drug development, currently with about 60 oncology drugs in clinical trials.
儘管Flatiron面臨着財務困境，但其數據已經極大地促進了羅氏的癌症藥物研發，目前該公司正在進行約60個腫瘤領域的臨床試驗。
The strategic review may not result in Flatiron changing hands, the FT report added.
《金融時報》報道補充稱，戰略審查可能不會導致Flatiron更換主人。
Last month, Roche announced topline results from two arms of an ongoing multi-part Phase 1 clinical trial for CT-996 for type 2 diabetes and obesity.
上個月，羅氏公佈了Ct-996治療2型糖尿病和肥胖症的多部分Ⅰ期臨床試驗的上市結果。
The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks.
數據顯示，Ct-996在沒有2型糖尿病的肥胖病人中治療4周後，平均體重損失較安慰劑組減少了6.1%，屬於臨床意義上的。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：本內容部分使用人工智能工具生成，並經Benzinga編輯審核發佈。